Related Experiment Video
Updated: Jun 7, 2026

Ileectomy-induced Bile Overaccumulation in Mouse Intestine
Published on: August 21, 2017
Bile acid sequestrants and diabetes: introduction and overview to the supplement
1Laboratory for Atherosclerosis and Metabolic Research, University of California Davis Medical Center, Sacramento, California, USA.
Abstract:
Diabetes is a global epidemic. The recommended goals for glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and blood pressure are achieved only in a very small minority of patients. In this supplement to Metabolic Syndrome and Related Disorders, we review the data showing that the bile acid sequestrant colesevelam lowers both HbA1c and LDL-C in patients with diabetes. These data make colesevelam an attractive therapy to get more patients to achieve their LDL-C and HbA1c goals.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Diabetes Mellitus: Introduction
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
